Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors.
A series of novel spirocyclic ethers were designed to function as nonpeptidal P2-ligands for HIV-1 protease inhibitors. Incorporation of designed ligands in the (R)-(hydroxyethylamino)sulfonamide isostere afforded potent HIV protease inhibitors.